AQST · Categories · Form 4

AQST - SEC Form 4 insider transactions

Aquestive Therapeutics Inc. (AQST) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for AQST

• 1d
  Chief Commercial Officer Korczynski Sherry covered exercise/tax liability with 2,714 shares, decreasing direct ownership by 1% to 238,403 units (SEC Form 4) (for withholding tax)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 22d
  Chief Legal Officer Zalewski Thomas A. was granted 100,000 shares (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 23d
  President and CEO Barber Daniel sold $35,413 worth of shares (8,257 units at $4.29), decreasing direct ownership by 1% to 660,574 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 23d
  SVP, Regulatory Affairs Cioffi Melina covered exercise/tax liability with 1,667 shares, decreasing direct ownership by 0.61% to 273,200 units (SEC Form 4) (withholding obligation)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 30d
  Corporate Secretary Braender Lori J covered exercise/tax liability with 135,690 shares, decreasing direct ownership by 37% to 231,042 units (SEC Form 4) to cover taxes

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 34d
  Chief People Officer Boyd Peter E. covered exercise/tax liability with 56,778 shares, decreasing direct ownership by 17% to 281,731 units (SEC Form 4) (for tax liability)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 34d
  President and CEO Barber Daniel covered exercise/tax liability with 335,922 shares, decreasing direct ownership by 33% to 668,831 units (SEC Form 4) to cover withholding tax

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 34d
  Chief Financial Officer Toth A Ernest Jr covered exercise/tax liability with 92,652 shares, decreasing direct ownership by 25% to 283,460 units (SEC Form 4) (for tax liability)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 34d
  Chief Operating Officer Jung Cassie covered exercise/tax liability with 72,734 shares, decreasing direct ownership by 26% to 202,246 units (SEC Form 4) (for tax liability)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 34d
  Corporate Secretary Braender Lori J covered exercise/tax liability with 76,147 shares, decreasing direct ownership by 17% to 366,732 units (SEC Form 4) (tax withholding)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 58d
  SEC Form 4 filed by Barber Daniel

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 58d
  SEC Form 4 filed by Boyd Peter E.

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 58d
  SEC Form 4 filed by Jung Cassie

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 58d
  SEC Form 4 filed by Toth A Ernest Jr

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 58d
  SEC Form 4 filed by Korczynski Sherry

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 58d
  SEC Form 4 filed by Braender Lori J

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 91d
  Chief People Officer Boyd Peter E. was granted 80,000 shares and sold $124,414 worth of shares (29,814 units at $4.17), increasing direct ownership by 17% to 338,509 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 91d
  President and CEO Barber Daniel sold $753,965 worth of shares (180,677 units at $4.17) and was granted 262,000 shares, increasing direct ownership by 9% to 1,004,753 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 91d
  Chief Legal Officer Braender Lori J was granted 80,000 shares and sold $167,346 worth of shares (40,102 units at $4.17), increasing direct ownership by 10% to 442,879 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 91d
  SVP, Regulatory Affairs Cioffi Melina was granted 100,000 shares and sold $105,623 worth of shares (25,311 units at $4.17), increasing direct ownership by 37% to 274,867 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 91d
  Chief Financial Officer Toth A Ernest Jr was granted 95,000 shares and sold $243,094 worth of shares (58,254 units at $4.17), increasing direct ownership by 11% to 376,112 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 91d
  Chief Commercial Officer Korczynski Sherry was granted 75,000 shares and sold $65,687 worth of shares (15,741 units at $4.17), increasing direct ownership by 33% to 241,117 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 91d
  Chief Operating Officer Jung Cassie was granted 80,000 shares and sold $191,086 worth of shares (45,791 units at $4.17), increasing direct ownership by 14% to 274,980 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 91d
  Chief Development Officer Davis Matthew W. was granted 50,000 shares, increasing direct ownership by 100% to 100,000 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 92d
  Chief Medical Officer Greenhawt Matthew J. was granted 75,000 shares (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 187d
  Chief People Officer Boyd Peter E. was granted 20,000 shares, increasing direct ownership by 7% to 288,323 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 188d
  SVP, Regulatory Affairs Cioffi Melina covered exercise/tax liability with 2,083 shares, decreasing direct ownership by 1% to 200,178 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 211d
  Chief Development Officer Davis Matthew W. was granted 50,000 shares (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 236d
  Chief Operating Officer Jung Cassie sold $473,701 worth of shares (67,575 units at $7.01) and exercised 25,000 shares at a strike of $3.10, decreasing direct ownership by 15% to 240,771 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 236d
  Chief Medical Officer Kraus Carl N sold $141,904 worth of shares (20,272 units at $7.00), decreasing direct ownership by 7% to 282,475 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 236d
  Officer Boyd Peter E. sold $70,000 worth of shares (10,000 units at $7.00), decreasing direct ownership by 4% to 268,323 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 254d
  President and CEO Barber Daniel sold $551,191 worth of shares (91,343 units at $6.03), decreasing direct ownership by 9% to 923,430 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 254d
  Officer Boyd Peter E. sold $63,000 worth of shares (10,000 units at $6.30), decreasing direct ownership by 3% to 278,323 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 261d
  President and CEO Barber Daniel sold $2,400 worth of shares (400 units at $6.00), decreasing direct ownership by 0.04% to 1,014,773 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 275d
  Chief Operating Officer Jung Cassie exercised 50,000 shares at a strike of $1.93 and sold $310,900 worth of shares (62,180 units at $5.00), decreasing direct ownership by 4% to 283,346 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 275d
  Officer Boyd Peter E. sold $79,500 worth of shares (15,000 units at $5.30), decreasing direct ownership by 5% to 288,323 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 300d
  Chief Commercial Officer Korczynski Sherry was granted 25,000 shares, increasing direct ownership by 16% to 181,858 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 303d
  Chief Medical Officer Kraus Carl N covered exercise/tax liability with 10,819 shares, decreasing direct ownership by 3% to 302,747 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 363d
  SEC Form 4 filed by Director Brown Gregory B

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 363d
  SEC Form 4 filed by Director Krop Julie

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 363d
  SEC Form 4 filed by Director Morris Timothy E

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 363d
  SEC Form 4 filed by Director Jenkins Abigail L.

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 363d
  SEC Form 4 filed by Director Cochran John

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 363d
  SEC Form 4 filed by Director Taglietti Marco

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 365d
  SVP Sales and Marketing Korczynski Sherry covered exercise/tax liability with 2,714 shares, decreasing direct ownership by 2% to 156,858 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 391d
  SVP, Regulatory Affairs Cioffi Melina was granted 20,000 shares, increasing direct ownership by 11% to 202,261 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 456d
  Chief Science Officer Wargacki Stephen was granted 115,000 shares and covered exercise/tax liability with 32,862 shares, increasing direct ownership by 31% to 343,552 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 456d
  Chief Operating Officer Jung Cassie was granted 80,000 shares and covered exercise/tax liability with 17,540 shares, increasing direct ownership by 27% to 295,526 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 456d
  Chief Financial Officer Toth A Ernest Jr was granted 110,000 shares and covered exercise/tax liability with 18,929 shares, increasing direct ownership by 37% to 339,366 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 456d
  Chief Medical Officer Kraus Carl N was granted 70,000 shares and covered exercise/tax liability with 8,115 shares, increasing direct ownership by 25% to 313,566 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 456d
  SVP Sales and Marketing Korczynski Sherry covered exercise/tax liability with 5,428 shares and was granted 90,000 shares, increasing direct ownership by 113% to 159,572 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 456d
  Chief Legal Officer Braender Lori J was granted 110,000 shares and covered exercise/tax liability with 20,250 shares, increasing direct ownership by 29% to 402,981 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 456d
  See Remark Boyd Peter E. was granted 80,000 shares and covered exercise/tax liability with 14,305 shares, increasing direct ownership by 28% to 303,323 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 456d
  President and CEO Barber Daniel was granted 272,000 shares and covered exercise/tax liability with 83,305 shares, increasing direct ownership by 23% to 1,015,173 units (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 553d
  Large owner Bratton Douglas K gifted 40,000 shares (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 560d
  Chief Operating Officer Jung Cassie sold $214 worth of shares (44 units at $4.87) (SEC Form 4)

  4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 616d
  Amendment: Chief Innovation/Tech Officer Schobel Alexander Mark covered exercise/tax liability with 9,645 shares, decreasing direct ownership by 0.97% to 980,726 units (SEC Form 4)

  4/A - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 616d
  Amendment: Chief Science Officer Wargacki Stephen covered exercise/tax liability with 19,505 shares, decreasing direct ownership by 7% to 261,414 units (SEC Form 4)

  4/A - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 616d
  Amendment: President and CEO Barber Daniel covered exercise/tax liability with 56,824 shares, decreasing direct ownership by 6% to 826,478 units (SEC Form 4)

  4/A - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
• 616d
  Amendment: SVP, Operations Jung Cassie covered exercise/tax liability with 14,120 shares, decreasing direct ownership by 6% to 233,066 units (SEC Form 4)

  4/A - Aquestive Therapeutics, Inc. (0001398733) (Issuer)

Other AQST categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends